Creation of the allergovaccines on the base of new technologies

The achievements of molecular immunology and allergology at the last years allow to create new hypoallergenic and effective allergovaccines for ASIT. The structure of leading allergen epitopes responsible for cross-reactivity in allergic process was decoded. It was shown, that allergen cross-reactivity appears to be all-biological phenomenon that creates the certain difficulties in the development of AV specific preparations. Recombinant allergens play the important role in standardization of diagnostic and medical forms of allergens and allow to get comparable results on IgE-linking activities of natural and recombinant forms in the skin and in vitro-tests. Usage of new technologies in creation of AV for ASIT is perspective. Recombinant allergens define a new strategy in the development of allergen-specific therapy. The prospects of new technologies using the development of AV with high effectiveness in treatment of patients with allergic diseases, is justified and will allow to get the safe medical preparations, which action is directed on creation of antiallergic immune response.